Seminars in Oncology
Volume 34, Issue 5 , Pages 428-434 , October 2007

Cowden Syndrome

  • Shanna Gustafson

      Affiliations

    • Center for Personalized Genetic Healthcare, Genomic Medicine Institute, Cleveland Clinic Foundation, Cleveland, OH.
    • ,
  • Kevin M. Zbuk

      Affiliations

    • Center for Personalized Genetic Healthcare, Genomic Medicine Institute, Cleveland Clinic Foundation, Cleveland, OH.
    • ,
  • Cheryl Scacheri

      Affiliations

    • Center for Personalized Genetic Healthcare, Genomic Medicine Institute, Cleveland Clinic Foundation, Cleveland, OH.
    • ,
  • Charis Eng

      Affiliations

    • Center for Personalized Genetic Healthcare, Genomic Medicine Institute, Cleveland Clinic Foundation, Cleveland, OH.
    • Department of Molecular Medicine, Cleveland Clinic Lerner College of Medicine, Cleveland, OH.
    • Department of Genetics, Case Western Reserve University School of Medicine, Cleveland, OH.
    • Corresponding Author InformationAddress correspondence to Charis Eng, MD, PhD, FACP, Genomic Medicine Institute, Cleveland Clinic Foundation, 9500 Euclid Ave, NE-50, Cleveland OH, 44195, USA.
    • C.E. is a recipient of the Doris Duke Distinguished Clinical Scientist Award.

References 

  1. Nelen MR, Padberg GW, Peeters EAJ, et al. Localization of the gene for Cowden disease to 10q22-23. Nature Genet. 1996;13:114–116
  2. Waite KA, Eng C. Protean PTEN: Form and function. Am J Hum Genet. 2002;70:829–844
  3. Eng C. PTEN: One gene, many syndromes. Hum Mutat. 2003;22:183–198
  4. Pilarski R, Eng C. Will the real Cowden syndrome please stand up (again)? (Expanding mutational and clinical spectra of the PTEN hamartoma tumour syndrome). J Med Genet. 2004;41:323–326
  5. Gorlin RJ, Cohen MM, Condon LM, et al. Banayan-Riley-Rvalcabe sydrome. Am J Med Genet. 1992;44:307–314
  6. Biesecker LG, Happle R, Mulliken JB, et al. Proteus syndrome: Diagnostic criteria, differential diagnosis and patient evaluation. Am J Med Genet. 1999;84:389–395
  7. Nelen MR, Kremer H, Konings IB, et al. Novel PTEN mutations in patients with Cowden disease: Absence of clear genotype-phenotype correlations. Eur J Hum Genet. 1999;7:267–273
  8. Eng C, Parsons R. Cowden syndrome. In:  Vogelstein B,  Kinzler KW editor. The Genetic Basis of Human Cancer. New York: McGraw-Hill; 1998;p. 519–526
  9. Marsh DJ, Coulon V, Lunetta KL, et al. Mutation spectrum and genotype-phenotype analyses in Cowden disease and Bannayan-Zonana syndrome, two hamartoma syndromes with germline PTEN mutation. Hum Mol Genet. 1998;7:507–515
  10. Eng C. Cowden syndrome. J Genet Counsel. 1997;6:181–191
  11. Longy M, Lacombe D. Cowden disease (Report of a family and review). Ann Genet. 1996;39:35–42
  12. Fackenthal JD, Marsh DJ, Richardson AL, et al. Male breast cancer in Cowden syndrome patients with germline PTEN mutations. J Med Genet. 2001;38:159–164
  13. Schrager CA, Schneider D, Gruener AC, et al. Clinical and pathological features of breast disease in Cowden’s syndrome: An underrecognised syndrome with an increased risk of breast cancer. Hum Pathol. 1997;29:47–53
  14. Reifenberger J, Rauch L, Beckmann MW, et al. Cowden’s disease: Clinical and molecular genetic findings in a patient with a novel PTEN germline mutation. Br J Dermatol. 2003;148:1040–1046
  15. Metcalfe K, Lynch HT, Ghadirian P, et al. Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. J Clin Oncol. 2004;22:2328-235
  16. Pilarski R, Eng C. Will the real Cowden syndrome please stand up (again)?Expanding mutational and clinical spectra of the PTEN hamartoma tumour syndrome. J Med Genet. 2004;41:323–326
  17. Marsh DJ, Dahia PL, Caron S, et al. Germline PTEN mutations in Cowden syndrome-like families. J Med Genet. 1998;35:881–885
  18. Eng C. Will the real Cowden syndrome please stand up: Revised diagnostic criteria. J Med Genet. 2000;37:828–830
  19. Mallory SB. Cowden syndrome (multiple hamartoma syndrome). Dermatol Clin. 1995;13:27–31
  20. Starink TM, van der Veen JP, Arwert F, et al. The Cowden syndrome: A clinical and genetic study in 21 patients. Clin Genet. 1986;29:222–233
  21. Harach H, Soubeyran I, Brown A, et al. Thyroid pathologic findings in patients with Cowden disease. Ann Diagn Pathol. 1999;3:331–340
  22. Hanssen AMN, Fryns JP. Cowden syndrome. J Med Genet. 1995;32:117–119
  23. Sweet K, Willis J, Zhou XP, et al. Molecular classification of patients with unexplained hamartomatous and hyperplastic polyposis. JAMA. 2005;294:2465–2473
  24. Kay PS, Soetikno RM, Mindelzun R, et al. Diffuse esophageal glycogenic acanthosis: An endoscopic marker of Cowden’s disease. Am J Gastroenterol. 1997;92:1038–1040
  25. Weber HC, Marsh D, Lubensky I, et al. Germline PTEN/MMAC1/TEP1 mutations and association with gastrointestinal manifestations in Cowden disease. Gastroenterology. 1998;114S:G2902
  26. Ambler M, Pogacar S, Sidman R. Lhermitte-Duclos disease (granule cell hypertrophy of the cerebellum) (Pathologic analysis of the first familial cases). J Neuropathol Exp Neurol. 1969;28:622–647
  27. Rebbeck TR, Friebel T, Lynch HT, et al. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: The PROSE Study Group. J Clin Oncol. 2004;22:1055–1062
  28. Fujio Y, Nguyen T, Wencker D, et al. Akt promotes survival of cardiomyocytes in vitro and protects against ischemia-reperfusion injury in mouse heart. Circulation. 2000;101:660–667
  29. Zdychova J, Komers R. Emerging role of Akt kinase/protein kinase B signaling in pathophysiology of diabetes and its complications. Physiol Res. 2005;54:1–16
  30. Sausville EA, Arbuck SG, Messmann R, et al. Phase I trial of 72-hour continuous infusion UCN-01 in patients with refractory neoplasms. J Clin Oncol. 2001;19:2319–2333
  31. Marsh DJ, Kum JB, Lunetta KL, et al. PTEN mutation spectrum and genotype-phenotype correlations in Bannayan-Riley-Ruvalcaba syndrome suggest a single entity with Cowden syndrome. Hum Mol Genet. 1999;8:1461–1472
  32. Hachicha M, Kammoun T, Chabchoub I, et al. Cowden’s disease: A new paediatric observation. Arch Pediatr. 2006;13:459–462
  33. Liaw D, Marsh DJ, Li J, et al. Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nat Genet. 1997;16:64–67
  34. Zhou XP, Waite KA, Pilarski R, et al. Germline PTEN promoter mutations and deletions in Cowden/Bannayan-Riley-Ruvalcaba syndrome result in aberrant PTEN protein and dysregulation of the phosphoinositol-3-kinase/Akt pathway. Am J Hum Genet. 2003;73:404–411
  35. Tamura M, Gu J, Danen EHJ, et al. PTEN interactions with focal adhesion kinase and suppression of the extracellular matrix-dependent phosphotidyinositol 3-kinase/Akt cell survival pathway. J Biol Chem. 1999;274:20693–20703
  36. Weng LP, Brown JL, Eng C. PTEN coordinates G1 arrest by down regulating cyclin D1 via its protein phosphatase activity and up regulating p27 via its lipid phosphatase activity. Hum Mol Genet. 2001;10:599–604
  37. Stambolic V, Suzuki A, de la Pompa JL, et al. Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell. 1998;95:29–39
  38. Li DM, Sun H. PTEN/MMAC1/TEP1 suppresses the tumorigenecity and induces G1 cell cycle arrest in human glioblastoma cells. Proc Natl Acad Sci U S A. 1998;95:15406–15411
  39. Di Cristofano A, Kotsi P, Peng YF, et al. Impaired Fas response and autoimmunity in Pten+/− mice. Science. 1999;285:2122–2125
  40. Chung JH, Eng C. Nuclear-cytoplasmic partitioning of phosphatase and tensin homologue deleted on chromosome 10 (PTEN) differentially regulates the cell cycle and apoptosis. Cancer Res. 2005;65:8096–8100

PII: S0093-7754(07)00146-7

doi: 10.1053/j.seminoncol.2007.07.009

Seminars in Oncology
Volume 34, Issue 5 , Pages 428-434 , October 2007

Article Tools

* Image Usage & Resolution